Cargando…

Emicizumab-induced photosensitivity

Emicizumab constitutes a novel and effective prophylaxis for hemophilia A patients with and without inhibitors. In this case report, we describe an emicizumab-induced photosensitivity that forced permanent sun-exposure suppression. To the best of our knowledge, this side effect had not been communic...

Descripción completa

Detalles Bibliográficos
Autores principales:	Asensi Cantó, Pedro, Rodríguez Serna, Mercedes, Lloret Madrid, Pilar, Solís Ruiz, Jürgen, Cid Haro, Ana Rosa, Bonanad Boix, Santiago, Haya Guaita, Saturnino
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Georg Thieme Verlag KG 2022
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9303071/ https://www.ncbi.nlm.nih.gov/pubmed/36046207 http://dx.doi.org/10.1055/s-0042-1749092

Ejemplares similares

Cerebral calcium embolism
por: Asensi Cantó, Pedro, et al.
Publicado: (2022)

Thromboembolic hazard in hereditary hemorrhagic telangiectasia
por: Asensi Cantó, Pedro, et al.
Publicado: (2022)

Predictive factors of immune tolerance treatment response in severe haemophilia A patients with inhibitors: A real‐world report from a single centre, mixed retrospective‐prospective long‐term study
por: Haya, Saturnino, et al.
Publicado: (2019)

The changing face of immune tolerance induction in haemophilia A with the advent of emicizumab
por: Carcao, Manuel, et al.
Publicado: (2019)

Emicizumab in children: bleeding episodes and outcome before and after transition to Emicizumab
por: Glonnegger, Hannah, et al.
Publicado: (2022)

Emicizumab state‐of‐the‐art update
por: Mahlangu, Johnny, et al.
Publicado: (2022)

Characterization of Anti-Emicizumab Antibodies Using Repository Samples Obtained in Clinical Studies of Emicizumab Conducted in Japan
por: Matsumoto, Naoki, et al.
Publicado: (2023)

Emicizumab Associated Rhabdomyolysis in Hemophilia A
por: Wilson, Joseph A., et al.
Publicado: (2020)

The dosing conundrum of emicizumab: To waste product or not?
por: Young, Guy
Publicado: (2023)

Utilization of Emicizumab in Acquired Factor VIII Deficiency
por: Hess, Kevin J., et al.
Publicado: (2020)

Low immunogenicity of emicizumab in persons with haemophilia A
por: Schmitt, Christophe, et al.
Publicado: (2021)

Disruptive technology and hemophilia care: The multiple impacts of emicizumab
por: Hermans, Cedric, et al.
Publicado: (2021)

P1616: EMICIZUMAB FOR THE MANAGEMENT OF ACQUIRED HEMOPHILIA A
por: Sridharan, Meera, et al.
Publicado: (2023)

Pharmacokinetics and Associated Efficacy of Emicizumab in Humans: A Systematic Review
por: Donners, Anouk A. M. T., et al.
Publicado: (2021)

Traumatic Tonsillar Hemorrhage during Hemophilia A Treatment with Emicizumab
por: Inoue, Fumiya, et al.
Publicado: (2022)

The effect of emicizumab and bypassing agents in patients with hemophilia – An in vitro study
por: Schultz, Nina Haagenrud, et al.
Publicado: (2021)

Efficacy of emicizumab is maintained throughout dosing intervals for bleed prophylaxis
por: Pipe, Steven W., et al.
Publicado: (2023)

Management of children with hemophilia A on emicizumab who need surgery
por: Belletrutti, Mark, et al.
Publicado: (2023)

Serious bleeds in pediatric persons with hemophilia A on emicizumab prophylaxis
por: Garcia, Jessica, et al.
Publicado: (2023)

Concomitant use of bypassing agents with emicizumab for people with haemophilia A and inhibitors undergoing surgery
por: Jiménez‐Yuste, Victor, et al.
Publicado: (2021)

Spotlight on emicizumab in the management of hemophilia A: patient selection and special considerations
por: Yada, Koji, et al.
Publicado: (2019)

Emicizumab Use in Treatment of Acquired Hemophilia A: A Case Report
por: Al-Banaa, Kadhim, et al.
Publicado: (2019)

Clinical Evidence and Safety Profile of Emicizumab for the Management of Children with Hemophilia A
por: Le Quellec, Sandra
Publicado: (2020)

Application of a hemophilia mortality framework to the Emicizumab Global Safety Database
por: Peyvandi, Flora, et al.
Publicado: (2020)

Kinetic analysis of ternary and binary binding modes of the bispecific antibody emicizumab
por: Mak, Stefanie, et al.
Publicado: (2022)

Anti-emicizumab antibodies do not cross-react with mim8 in vitro
por: Valsecchi, Carla, et al.
Publicado: (2023)

Emicizumab prophylaxis for people with hemophilia A: Waste estimation and the Brazilian perspective
por: Camelo, Ricardo Mesquita, et al.
Publicado: (2023)

Bridging the Missing Link with Emicizumab: A Bispecific Antibody for Treatment of Hemophilia A
por: Gelbenegger, Georg, et al.
Publicado: (2020)

Real-World Data on Bleeding Patterns of Hemophilia A Patients Treated with Emicizumab
por: Levy-Mendelovich, Sarina, et al.
Publicado: (2021)

Emicizumab in acquired haemophilia A: about two clinical cases and literature review
por: Hansenne, Amandine, et al.
Publicado: (2021)

Anticoagulation for Stroke Prevention after Restoration of Haemostasis with Emicizumab in Acquired Haemophilia A
por: Al-Banaa, Kadhim, et al.
Publicado: (2021)

Cerebellar hematoma in severe hemophilia with inhibitor on emicizumab prophylaxis: a case report
por: Albattat, Sami, et al.
Publicado: (2023)

Evaluation of the Pharmacokinetics, Pharmacodynamics, and Safety of a Single Dose of Emicizumab in Healthy Chinese Subjects
por: Li, Haiyan, et al.
Publicado: (2020)

Absence of Effect of Emicizumab on D-Dimer Concentrations in Adult Patients with Severe Hemophilia A
por: Iarossi, Michael, et al.
Publicado: (2022)

Emicizumab dose up‐titration in case of suboptimal bleeding control in people with haemophilia A
por: Schmitt, Christophe, et al.
Publicado: (2022)

Factor VIII inhibitors in hemophilia A treated with emicizumab: longitudinal follow-up of outcomes
por: Levy-Mendelovich, Sarina, et al.
Publicado: (2023)

PB2647: USE OF EMICIZUMAB FOR THE TREATMENT OF ACQUIRED HEMOPHILIA A: A SYSTEMATIC REVIEW
por: Al-Housni, Zainab, et al.
Publicado: (2023)

Model of Short- and Long-Term Outcomes of Emicizumab Prophylaxis Treatment for Persons with Hemophilia A
por: Zhou, Zheng-Yi, et al.
Publicado: (2020)

Allogeneic hematopoietic cell transplantation in an adult patient with Glanzmann thrombasthenia
por: Cid, Ana R., et al.
Publicado: (2017)

Photosensitive rash induced by nivolumab()
por: Navarro-Triviño, Francisco J., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_ri90u8fo5uueqvj51f9tm9bkvv